Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 989 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diseases of the Musculoskeletal System and Connective Tissue Clear all
Recruiting No phase listed Observational

Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone

NCT05033288
View directory record Official record
Conditions
Bone Sarcoma, Chondrosarcoma, Chordoma, Ewing Sarcoma of Bone, Pelvic Rhabdomyosarcoma
Interventions
Electronic Health Record Review, Quality-of-Life Assessment
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
15 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Results available

Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis

NCT00847886
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LX3305, LX3305 Placebo, Methotrexate
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2010 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Not applicable Interventional

Efficacy & Safety Study of Natural Eggshell Membrane (NEM) for the Treatment of Joint & Connective Tissue Disorders

NCT00750854
View directory record Official record
Conditions
Osteoarthritis, Fibromyalgia
Interventions
NEM Formulation X, NEM Formulation Y
Dietary Supplement
Lead sponsor
ESM Technologies, LLC
Industry
Eligibility
18 Years to 100 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Jenks, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 25, 2026, 10:41 AM EDT
Terminated No phase listed Observational

Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18:

NCT00615628
View directory record Official record
Conditions
Osteosarcoma, Paget's Disease
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 25, 2026, 10:41 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

The Efficacy of Liposomal Bupivacaine in Ultrasound Guided Supraclavicular Nerve Blocks for Hand and Wrist Surgery

NCT06806410
View directory record Official record
Conditions
Hand Surgery, Wrist Surgery, Elbow Surgery, Fracture Fixation, Dupuytren Contracture, Finger Fracture, Wrist Arthropathy, Distal Radius Fracture
Interventions
Liposomal bupivacaine (LB), Dexamethasone
Drug
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 25, 2026, 10:41 AM EDT
Terminated Phase 2 Interventional

A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

NCT06312020
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
HZN-1116, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Mesa, Arizona • Phoenix, Arizona • Napa, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy

NCT00468546
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MabThera/Rituxan, Methotrexate, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
67
States / cities
Birmingham, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab

NCT02296424
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis (SJIA)
Interventions
ACZ885 150 mg (Canakinumab)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 20 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Los Angeles, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 25, 2026, 10:41 AM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

An Interventional Study of Infigratinib in Children With Hypochondroplasia

NCT06873035
View directory record Official record
Conditions
Hypochondroplasia
Interventions
infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
3 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study Evaluating the Safety and Efficacy of Cura-100 in Subjects With Rheumatoid Arthritis and Osteoarthritis

NCT00455208
View directory record Official record
Conditions
Rheumatoid Arthritis, Osteoarthritis
Interventions
Cura-100
Drug
Lead sponsor
Cura Biotech LLC
Industry
Eligibility
20 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2009 · Synced Oct 25, 2026, 10:41 AM EDT
Active, not recruiting Not applicable Interventional

Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System

NCT03626038
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Post-Traumatic Arthritis, Psoriatic Arthritis, Proximal Humeral Fracture
Interventions
A.L.P.S. Proximal Humerus Plating System
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Not applicable Interventional Results available

The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis

NCT02984943
View directory record Official record
Conditions
RheumatoId Arthritis
Interventions
Hyperbaric Oxygen
Device
Lead sponsor
David Grant U.S. Air Force Medical Center
Federal
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Travis Air Force Base, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 25, 2026, 10:41 AM EDT
Enrolling by invitation Phase 1 Interventional

A Study of KITE-363 in Participants With Refractory Autoimmune Diseases

NCT07038447
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis, Idiopathic Inflammatory Myopathy
Interventions
KITE-363, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Duarte, California • Stanford, California • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 2 Interventional

Methimazole to Treat Polymyositis and Dermatomyositis

NCT00001421
View directory record Official record
Conditions
Dermatomyositis, Polymyositis
Interventions
methimazole
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis

NCT01885078
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2,877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
67
States / cities
Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

A Study in Moderate to Severe Rheumatoid Arthritis

NCT01710358
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Baricitinib, Methotrexate, Adalimumab Placebo, Baricitinib Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
45
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 1 Interventional

The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis

NCT00001614
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid, Uveitis
Interventions
Chicken type II collagen
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 10:41 AM EDT
Active, not recruiting Not applicable Interventional

Clear Aligners for the Treatment of Dental Malocclusion in OI

NCT04815564
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Invisalign
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 40 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis

NCT00550043
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
INCB018424, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Huntsville, Alabama • Upland, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 25, 2026, 10:41 AM EDT
Recruiting Phase 1 Interventional

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

NCT06581562
View directory record Official record
Conditions
Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
Interventions
AB-101, Rituximab, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
IRIS Research and Development, LLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis

NCT00554606
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Canakinumab
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
20
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome

NCT02291029
View directory record Official record
Conditions
Primary Sjögren's Syndrome
Interventions
CFZ533 active - Cohort 1, CFZ533 placebo- Cohort 1, CFZ533 active - Cohort 2, CFZ533 placebo - Cohort 2, CFZ533 active - Cohort 3
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Mineola, New York • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 1Phase 2 Interventional

ADX-629 Therapy for Sjogren-Larsson Syndrome

NCT05443685
View directory record Official record
Conditions
Sjogren-Larsson Syndrome
Interventions
ADX-629
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
5 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis

NCT02969525
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Placebo, Bimekizumab
Other · Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
13
States / cities
San Diego, California • Aventura, Florida • Hagerstown, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 25, 2026, 10:41 AM EDT